Hederasaponin derivative, preparation method of salts thereof and application thereof to resisting tumor
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of hedera saponins and derivatives, applied in the field of medicine, to achieve strong anti-tumor activity
Active Publication Date: 2011-09-28
JIANGXI HERBFINE HI TECH
View PDF3 Cites 10 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
For 3-O-α-L-rhamnopyranose-(1→2)[β-D-glucopyranose-(1→4)]-α-L-arabinopyranose hedera derivatives , its salt and its use have not been reported yet
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0024] Example 1: Preparation of 3-O-α-L-rhamnopyranose-(1→2)[β-D-glucopyranose-(1→4)]-α-L-arabinopyranose ivy Saponin methyl ester (compound 1)
[0025] 3-O-α-L-rhamnopyranose-(1→2)[β-D-glucopyranose-(1→4)]-α-L-arabinopyranosyl hedera saponin (0.9g, 1 mmol) was dissolved in methanol (10 mL), ice-water bath, added CDI (N,N'-carbonyldiimidazole 0.32 mg, 2 mmol), stirred at room temperature for 2 h, concentrated under reduced pressure, added 50 mL of water, a large amount of solid precipitated , suction filtered, washed with water, and dried to obtain a white solid (65%).
Embodiment 2
[0026] Example 2: Preparation of 3-O-α-L-rhamnopyranose-(1→2)[β-D-glucopyranose-(1→4)]-α-L-arabinopyranose ivy Saponinethyl ester (Compound 2)
[0027] 3-O-α-L-rhamnopyranose-(1→2)[β-D-glucopyranose-(1→4)]-α-L-arabinopyranosyl hedera saponin (0.9g, 1 mmol) was dissolved in ethanol (10 mL), ice-water bath, added CDI (N,N'-carbonyldiimidazole 0.32 mg, 2 mmol), stirred at room temperature for 2 h, concentrated under reduced pressure, added 50 mL of water, a large amount of solid precipitated , suction filtered, washed with water, and dried to obtain a white solid (60%).
Embodiment 3
[0028] Example 3: Preparation of 3-O-α-L-rhamnopyranose-(1→2)[β-D-glucopyranose-(1→4)]-α-L-arabinopyranose ivy Saponinformamide (compound 3)
[0029] The saponin 3-O-α-L-rhamnopyranose-(1→2)[β-D-glucopyranose-(1→4)]-α-L-arabinopyranose hedera saponin (0.9 g, 1 mmol) was dissolved in THF (10 mL), ice-water bath, added CDI (0.32 mg, 2 mmol), stirred at room temperature for 2 h, the reaction solution was added dropwise to 40% aqueous methylamine solution, concentrated under reduced pressure, added 50 mL of water, a large amount of solid was precipitated, suction filtered, washed with water, and dried to obtain a white solid (75%).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention belongs to the technical field of medicines and provides a 3-O-alpha-L-pyranrhamnose-(1->2) [beta-D-glucopyranose-(1-4)]-alpha-L-pyranarabinose hederasaponin derivative, a preparation method of salts thereof and application thereof to resisting tumor. The structures of the hederasaponin 3-O-alpha-L-pyranrhamnose-(1->2) [beta-D-glucopyranose-(1->4)]-alpha-L-pyran arabinose hederasaponin derivative and salts thereof are shown as follows. The hederasaponin 3-O-alpha-L-pyran rhamnose-(1->2) [beta-D-glucopyranose-(1->4)]-alpha-L-pyran arabinose hederasaponin derivative and the salts thereof are combined with a pharmaceutical acceptable carrier to form a pharmaceutical compound which is used for preparing tumor-resistant medicines. Compared with the prototype medicine, a medicine containing the ingredient derivative and the salts thereof has considerable or stronger tumor-resistant activity; and meanwhile, the activity of other tumor-resistant medicines can be obviously enhanced and the side effects of the medicines are reduced.
Description
technical field [0001] The invention belongs to the technical field of medicine, and relates to a hedera saponins component 3-O-α-L-rhamnopyranose-(1→2)[β-D-glucopyranose-(1→4)]- α-L-arabinopyranosyl hedera saponin derivative, the preparation method of its salt and its anti-tumor application. The medicine containing the component derivatives and their salts provided by the invention has equivalent or stronger antitumor activity than the original medicine, and can also obviously enhance the activity of other antitumor medicines and reduce the toxic and side effects of these medicines. Background technique [0002] 3-O-α-L-rhamnopyranose-(1→2)[β-D-glucopyranose-(1→4)]-α-L-arabinopyranose hedera saponin has a strong Anti-tumor activity, can inhibit human tumor cells (human glioma, human livercancer, human erythroleukemia, human moderately differentiated gastric adenocarcinoma, human breastcancer, human cervical cancer, human poorly differentiated gastric gland, human promyel...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more